PharmacoVigilance: Development of PhV systems and processes VICH Workshop, Dar Es Salaam, Tanzania, 24 June 2015.

Slides:



Advertisements
Similar presentations
MODULE TWO Practical Tips for Participation in CPM and IPPC Activities.
Advertisements

Session 6 : Need for good governance Importance of veterinary legislation and its appropriate implementation Jean-Luc ANGOT, CVO, France 14 March 2013.
Disclaimer The presentation is intended for educational purposes only and does not replace independent professional judgement. Statements of fact and opinions.
Merton V. Smith, Ph.D., J.D. Director International Programs Center for Veterinary Medicine U.S. Food and Drug Administration Governance of Veterinary.
1 Proposed Pharmacovigilance Plan for H5N1 Influenza Virus Vaccine Patrick Caubel, MD, PhD Head of Pharmacovigilance North America February 27, 2007.
1 The European Commission's Proposal to Re-design Existing European Drug Safety Rules An Industry View on Practical Implications Margaret Walters – Merck,
Objectives Why we need DHCPL Situations that call for a DHCPL Definitions DHCPL itself–content, presentation, process Target audience Current and future.
Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.
European Commission Enterprise and Industry Market surveillance and automotive type-approval legislation - 28/06/2012 | ‹#› WP.29 Enforcement Working Group.
EMEA / IFAH–Europe Info Day « Balancing the benefits and risks of Veterinary Medicinal Products »
The Quality Management System
The Sixth Annual African Consumer Protection Dialogue Conference
Reconstruction of the Pharmacovigilance System
1 Inspection of LCPs: System for Inspection. ECENA Training Workshop Bristol, March 2008.
IPhVWP Polish Presidency, Warsaw October 6 th 2011 Almath Spooner Irish Medicines Board Monitoring the outcome of risk minimisation activities.
Requirements of EU pharmacovigilance legislation for distributors Julia Sipos Quality Management Director Pharmacovigilance coordinator Version 03.
Regulatory Update Ellen Leinfuss SVP, Life Sciences.
OFFICIAL CONTROL OF FOOD LABELLING AND FOOD QUALITY CONTROL Dr. Pirjo-Liisa Penttilä Ministry of Agriculture and Forestry Finland.
Benefits of a strong collaboration with patient groups at national and EU level Susanna Palkonen, Director European Federation.
Project co-financed by European Union Project co- financed by Asean European Committee for Standardization Implementing Agency 1 Module 13 GMP Workshop.
Pharmacovigilance obligations of the Pharmaceutical companies in India
DPG HEALTH MEETING USAID CONFERENCE ROOM 6 NOVEMBER 2013 International Health Regulation (2005)
H. Lundbeck A/S21-Sep-151 Pharmacovigilance during clinical development SAE reporting, ASUR and PSUR IFF Seminar, 21. February 2007.
Adverse Event Management from the HSE perspective E. Cennini / DGS-SEE EDMS Id Adverse events Workshop Creating a common understanding.
An agency of the European Union Presented by: David Mackay Head of Unit, Veterinary Medicines & Product Data Management Unit Incident Management Plan Veterinary.
Chapter 6 CRISIS MANAGEMENT. Introduction - Crisis: ◦is a situation that specifically involves a pharmaceutical product, medical device or activity with.
European Enforcement of Pharmacovigilance and Inspection Trends Is compliance possible within the EU? June 7, 2007 Dr. M.C. Koster CEO Vigilex Group.
The revised EU Cosmetics Legislation
SEVESO II transposition and implementation – possible approaches and lessons learned from MS/NMS SEVESO II transposition and implementation – possible.
1 Pesticide Program Dialogue Committee Meeting State Lead Agency Presentation Chuck Andrews, Chair AAPCO Worker Protection Committee California Department.
Directorate General for Enterprise and Industry European Commission The New Legislative Framework - Market Surveillance UNECE “MARS” Group meeting Bratislava,
Twinning project ENEA – ENforcing Environmental Acquis Skopje, 19 th of November, 2015.
FDA Regulatory and Compliance Symposium
The New EU Legislative Framework for Harmonisation Legislation for products Richard Lawson Deputy Director, Technical Regulations Sustainable Development.
Update on EU Issues 10 th March 2010 Manchester Conference Centre Health and Safety Executive Major Hazards Policy Team Paul Edwards.
SEVESO II transposition and implementation: Possible approaches and lessons learned from member states and new member states SEVESO II transposition and.
European Patients’ Academy on Therapeutic Innovation Aspects of pharmacovigilance: Periodic Safety Update Reports (PSURs)
Overcoming challenges in pediatric oncology product development: Regulatory oversight of multi-national clinical studies Ursula Kern, Advisory Committees.
Creating the environment for business Assessment of the Implementation by the Member States of the IPPC Directive Advisory Group Meeting Friday 13 th January.
Gdansk International Air & Space Law Conference November 2013 Authority and Organisation Requirements “effective management systems for authorities and.
PharmacoVigilance: Development of PhV systems and processes.
Role of VICH and VICH guidelines in the approval process for veterinary medicinal products David Mackay, European Medicines Agency VICH Workshop – Dar.
JMAFF (Chair of Biologicals Quality Monitoring EWG)
VICH General Principles and current update of VICH Outreach Forum activity 1.
Health and Food Safety EU strategy for Pharmaceuticals in the Environment Patrizia Tosetti DG SANTE European Commission China/EU Pharmaceutical Industry.
VICH Training Strategy Steven D. Vaughn, DVM Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine U.S. Food and Drug Administration.
Introduction to the VICH Outreach Forum Steven D. Vaughn, DVM VICH Workshop Dar Es Salaam, Tanzania – June 24, 2015.
Slide n° 1 EU railway legislation - Safety regulatory framework NAB/RB training workshop in Valenciennes, April 2016 NAB/RB Training Workshop In Valenciennes,
1 VICH AND VETERINARY MEDICINES AVAILABILITY VICH5 CONFERENCE, OCTOBER 2015, TOKYO VICH AND VETERINARY MEDICINES AVAILABILITY VICH5 CONFERENCE, OCTOBER.
Organization and Implementation of a National Regulatory Program for the Control of Radiation Sources Program Performance Criteria.
WORKSHOP ON ACCREDITATION OF BODIES CERTIFYING MEDICAL DEVICES INT MARKET TOPIC 6 CH 5 ISO MANAGEMENT RESPONSIBILITY Philippe Bauwin Medical.
How to get involved in VICH Dr. Allen Bryce Independent consultant Canberra, Australia VICH Workshop: Dar Es Salaam, Tanzania – 24.
1 PHARMACOVIGILANCE & THE NATIONAL ADVERSE DRUG REACTION (ADR) REPORTING SYSTEM Sarah Spiteri Post-Licensing Directorate Medicines Authority.
1 The contribution of VICH to the global One Health approach VICH5 CONFERENCE, OCTOBER 2015, TOKYO Jean-Pierre Orand, Anses, France, OIE Collaborating.
Principles of Risk Management
Periodic Safety Update Reports (PSUR)
11 vii. Consolidate aDSM data electronically
EudraVigilance.
REGULATORY PROBLEMS IN CARING OUT PRE- AND POST- AUTHORISATION CLINICAL TRIALS Dr Penka Decheva GCP Inspector, BDA.
Pharmacovigilance in clinical trials
Establishing the Infrastructure for Radiation Safety Preparatory Actions and Initial Regulatory Activities.
TAIEX, Istanbul, April 19th, 2011
The role of the HPRA in the authorisation of veterinary medicinal products The role of the Health Products Regulatory Authority in the authorisation of.
Helen Lee, European Commission
How Can I Get More Information on VICH?
The International Drug Safety Paradigm
How to use the pharmacovigilance (PhV) guidelines (GLs)
Pharmacovigilance updates
Neopay Practical Guides #2 PSD2 (Should I be worried?)
Pharmacovigilance inspections: what HPRA expects
Presentation transcript:

PharmacoVigilance: Development of PhV systems and processes VICH Workshop, Dar Es Salaam, Tanzania, 24 June 2015

2  Systematic surveillance of all authorised veterinary medicinal products  Ensure safe and effective products on the market  Fast and proportional action on signals from data analysis  Active crisis management with good and open communication The goal of pharmacovigilance:

3 Different levels of PhV systems > Estimate the need and expectation depending on > Existing PhV system or starting new > Financial and personnel resources > Size of country or region > Husbandry production and medicinal use > Cooperation with other authorities > Legislation

4 Developing the PhV system > Draft legislation framework for PhV (avoid details) > Plan PhV-system in competent authority: responsibility, level of ambition, cooperation in region, practical work, etc > Define responsibilities and obligations of companies > Align with international definitions > Consult draft plans with stakeholders – companies and vets > Establish necessary documentation and systems Reporting form for adverse events (AE) Filing system for AE-reports: Paper  small electronic system  database Tools for analysis of data; signal detection; trend analysis; trigger thresholds Operating procedures Feedback communication

5 Implementing the PhV system > Training? > Communication and awareness plan Make companies and vets aware of their obligations Set deadline for companies to implement in-house systems and procedures (compliance) Spread the PhV-understanding to vets/users/owners > Standard reporting form available on website, paper, by telephone, on conferences, etc > Data input management > Start analysing across substances, products, species > Consider using a risk-based approach, where the surveillance intensity is proportional to the expected risk level

6 1. PhV requirements in legislation > Definitions of adverse events, scope of PhV, surveillance, timelines ~ (VICH GLs) > Obligation for companies to receive AE-reports from vets/users/owners analyse the AE-reports and survey their products in general inform authorities. > Possibility for authorities to inspect or control that companies comply analyse data from PhV or other sources take necessary actions based on PhV. > Possibility/obligation for vets/users/owners to report directly to authorities.

7 2. Plan PhV-system in authority > Define PhV-responsibility (who does what) > Realistic ambitions > Aim for regional cooperation if possible, because large-scale PhV-data are more useful and work-sharing between authorities is beneficial > The company should be responsible for the PhV surveillance and PhV reporting of their products > The authority should perform controls, product group analysis and request corrective actions

8 The responsibility of the authority > To establish a PhV system: collect information evaluate scientifically collate with data on use monitor compliance of companies do inspections take action > Initiate assessment of safety concerns > Define risk management measures or implement conditions and restrictions on products > Encourage reporting of adverse events by vets/users/owners > Communicate safety concerns and mitigation measures

9 Spread the PhV-understanding > Encourage reporting: Receipt letter to vets/users/owners, (and companies) who have reported AEs Personal response to a few reporters if additional information is needed Annual PhV-report in Vet magazine PhV-presentation for all graduating vets > Education: module on PhV in vet university > Ad-hoc presentations at vet conferences and Industry association meetings > AE-reporting form easily available

10 Filing system for AE-reports > From paper small electronic system database > Simple (vet-specific) database with international compatibility is preferable > Tools for analysing data in the database are VERY important! > There are hurdles for a large regional/international database, for example: IT-compatibility for existing national databases Product database (same product with different names must be ”linked”) Who is responsible for analysing data ”Access to data”-agreements

11 EU experience > Pharmacovigilance system based on Spontaneous reports PHV Database and product database Periodic Safety Update Reports (defined reporting dates) Signal detection in database > Follow-up and changes to product information when necessary > PhV inspections > Information to vets, users and owners about safe use of products, which is what PhV is really about! (footnote 2015: The EU legislation is currently under revision, also concerning pharmacovigilance requirements)

12 EU-Pharmacovigilance scope > Animal safety serious and non-serious adverse reactions > Lack of expected efficacy > Off-label use / misuse > Humans reacting after exposure > Violations of residue levels > Potential environmental problems

13 Practical approach in national agency: spontaneous AE-reports Immediately after AE-report is received: > Apply case-number and letter of receipt > Causality assessment by Agency-vet > Decision on action/no-action, or request more information, etc > PhV-report forwarded to Company NB: Protection of personal data of reporter/owner may be required > Filing in national and/or in EU database (at EMA)

14 Practical approach in national agency: PSURs > Periodic safety update reports (PSURs) are received from the companies in a periodic schedule, or on request includes all AE-reports and other PhV-information since last PSUR and a benefit-risk evaluation for the product Received and assessed for national products Work share for regional products (i.e. EU region) Agreement on fixed data lock-points per substance Letter to company: OK, or occasionally changes in the product information/leaflet, or further investigation requested.

15 Minimal requirements of an AE report > Identifiable reporter > Animal (species) > Suspected product > Adverse event > However, many more details are desired and possible to fill in to the database/reporting form

16 Other PhV information exchange between authorities > Rapid Alert (EUDRANET = Secure intranet system between all EU authorities): sent to all member states, if urgent actions are needed > Non-Urgent Information System: to share and discuss specific trends or cases between member states

17 Reference documents (EU) > Regulation (EC) No 726/2004 (Title III Chapter 3) and > Directive 2001/82/EC (Title VII) > Volume 9 (b) – Guidelines on Pharmacovigilance for Medicinal Products for Veterinary Use.

18